Incidence of type 2 diabetes mellitus and cardiovascular disease in familial combined hyperlipidemia

Completed

Conditions: familial combined hyperlipidemia
genetically elevated cholesterol and triglycerides levels
10011082
10018424
10013317

Registration Number: NL-OMON40391

Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 452

Inclusion Criteria

All subjects, i.e. FCHL patients, their normolipidemic relatives and spouses, who have been included in our initial cohort (initiated in 1998) wil be invited for this study

Exclusion Criteria

As this study is a follow-up study, all subjects who have been included in the original cohort will be invited, except for: 1) subjects who have previously rejected any further participation 2) subjects with impaired cognitive function to give informed consent.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1) 10-years incidence of T2DM<br /><br>2) 10-years incidence of CVD</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) Baseline predictors of incident T2DM; baseline predictors of interest are<br /><br>age, sex, body mass index, waist circumference, plasma glucose and insulin<br /><br>levels. Additional factors of interest are genetic factors.<br /><br>2) Baseline predictors of incident CVD; baseline predictors of interest are<br /><br>age, sex, body mass index (BMI), waist circumference, systolic blood pressure,<br /><br>diastolic blood pressure, smoking status, plasma glucose, HDL-cholesterol,<br /><br>LDL-cholesterol, apolipoprotein B and total cholesterol levels, which have been<br /><br>determined at baseline in all subjects.<br /><br>3) Compliance to current primary and secondary CVD prevention strategies;<br /><br>clinical parameters of interest are systolic and diastolic blood pressure,<br /><br>plasma HbA1c and LDL-cholesterol levels at follow-up.<br /><br>4) The prevalence of CESD in dyslipidemic FCHL pedigrees</p><br>